The role of E255K/V-inclusive mutations in a Philadelphia-positive acute lymphoblastic leukemia with mutation evolution during sequential TKIs therapies: A case report

RATIONALE: Until recently, the survival rate in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) was approximately 30%. Tyrosine kinase inhibitors (TKIs), which are a new class of drugs that target BCR-ABL fusion protein, have shown to be effective in treating Ph+ ALL in ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Miaomiao, Gui, Xiya, Wu, Qiuling, Xia, Linghui, Wang, Yadan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104221/
https://www.ncbi.nlm.nih.gov/pubmed/33950935
http://dx.doi.org/10.1097/MD.0000000000025579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104221/
https://www.ncbi.nlm.nih.gov/pubmed/33950935
http://dx.doi.org/10.1097/MD.0000000000025579

Ejemplares similares